Hepatitis A Profile: Epidemiological, Clinical and Outcomes in Children’s Welfare Teaching Hospital and the Need for Hepatitis A Vaccine Programme Setting
DOI:
https://doi.org/10.32007/jfacmedbaghdad2410Keywords:
ALF, Children’s Welfare Teaching Hospital, Encephalopathy, HAV vaccine, HepatitisAbstract
Background: Hepatitis A virus, a single-stranded RNA virus from the family Picornaviridae, is primarily transmitted via the fecal-oral route. The World Health Organization reports about 1.5 million hepatitis A cases annually, with the incidence rates closely linked to socioeconomic conditions. This vaccine-preventable disease is the focus of our research.
Objectives: The current research aimed to elucidate the incidence, clinical presentation, and outcomes of hepatitis A in Iraq, highlighting the importance of appropriate preventive measures.
Methods: It wasconducted as a retrospective cohort study from January 2019 to July 10, 2022, and a prospective cohort study from July 11, 2022, to September 30, 2022. A total of 238 confirmed HAV cases 189 retrospective and 49 prospective were analyzed. Data included demographic characteristics, clinical presentations, laboratory findings, and ultrasonographic results. HAV IgM positivity was confirmed using the MAGLUMI HAV IgM Chemiluminescent Immunoassay CLIA).
Results: Most cases were observed in the 6 to 10-year-old age group p=0). Gender distribution was nearly equal, with males at 50.8% and females at 49.2%. Clinical profiles included jaundice 96.2%), hepatomegaly 45.4%), abdominal distention 15.6%), splenomegaly 7%), and bleeding 5.9%). Ultrasound findings showed an enlarged liver 45.4%), thickened edematous gallbladder wall 31.2%), enlarged spleen 14.9%), and ascites 4.2%). Biochemical analysis revealed mean values of SGPT 786.8 U/l), SGOT 647.6 U/l), TSB 10.34 mg/dl), Alb 3.9 g/dl), PT 14.9 sec), PTT 36.45 sec), and INR 1.15). Severe cases were 8 in number, with acute liver failure 4 deaths) and 6 with hepatic encephalopathy 5 deaths), and a mortality rate of 2.1% of which the male-to-female ratio was 4:1.
Conclusion: This study underscores the need for vaccine implementation to prevent and control HAV infection in Iraq, given the high incidence and ongoing risks.
Received: June 2024
Revised: Dec. 2024
Accepted: Jan. 2025
Published April 2025
Downloads
References
1. Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol. 2022 Apr 14;2814):1405-1429.PMID: 35582678; PMCID: PMC9048475.Hollinger FB, Liang TJ. Hepatitis B virus. Fields virology. Lippincott Williams & Wilkins, Philadelphia. 2017:2971-3036.https://doi.org/10.3748/wjg.v28.i14.1405.
2. Abutaleb A, Kottilil S. Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention. GastroenterolClin North Am. 2020 Jun;492):191-199. Epub 2020 Mar 29. PMID: 32389358;PMCID:PMC7883407.https://doi.org/10.1016/j.gtc.2020.01.002.
3. Aggarwal R, Goel A. Hepatitis E: current status in India. Clin Liver Dis
Hoboken). 2021;183):168-172. https://doi.org/10.1002/cld.1040PMid:33163170 PMCid:PMC7609704
4. Pérez-Sautu U, Costafreda MI, Caylà J, Tortajada C, Lite J, Bosch A, Pintó RM. Hepatitis a virus vaccine escape variants and potential new serotype emergence. Emerg Infect Dis. 2011 Apr;174):734-7. Https://doi.org/10.3201/eid1704.101169. PMID: 21470474; PMCID: PMC3377408.
5. Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, Koneru A, Byrd KK. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69No. RR-5):1-38. https://doi.org/10.15585/mmwr.rr6905a1.
PMid:32614811 PMCid:PMC8631741
6. Gabrielli F, Alberti F, Russo C, Cursaro C, Seferi H, Margotti M, Andreone P. Treatment Options for Hepatitis A and E: A Non-Systematic Review. Viruses. 2023 Apr 28;155):1080. Https://doi.org/10.3390/v15051080. PMID: 37243166; PMCID: PMC10221699.
7. UFallucca A, Restivo V, Sgariglia MC, Roveta M, Trucchi C. Hepatitis a Vaccine as Opportunity of Primary Prevention for Food Handlers: A Narrative Review. Vaccines Basel). 2023 Jul 21;117):1271. Https://doi.org/10.3390/vaccines11071271. PMID: 37515087; PMCID: PMC10383099.
8. Dhawan A, Cheeseman P, Mieli-Vergani G. Approaches to acute liver failure in children. Pediatr Transplant. 2020;244):e13678.https://doi.org/10.1111/petr.13678 PMid:32343885
Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol. 2021 Apr 28;2716):1691-1715. Https://doi.org/10.3748/wjg.v27.i16.1691. PMID: 33967551; PMCID: PMC8072198.
9. Migueres M, Lhomme S, Izopet J. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses. 2021;1310):1900. doi:10.3390/v13101900 https://doi.org/10.3390/v13101900
PMid:34696330 PMCid:PMC8540458
10. Langan RC, Goodbred AJ. Hepatitis A. Am Fam Physician. 2021 Oct 1;1044):368-374. PMID: 34652109.
11. Zhang L. Hepatitis A vaccination. Hum VaccinImmunother. 2020 Jul 2;167):1565-1573. Epub 2020 Jul 10. PMID: 32649265; PMCID: PMC7482852.https://doi.org/10.1080/21645515.2020.1769389
12. Abu-Raddad LJ, Ayoub HH, Chemaitelly H, Mumtaz GR, Butt AA, May MT, Hallett TB. Characterizing the Epidemiology of Hepatitis A in the Middle East and North Africa: Implications for Vaccination Strategies. Journal of Infection and Public Health. 2021;144):409-420.
https://doi.org/10.1016/j.jiph.2021.01.002PMid:33743368PMCid:PMC7834000
13. Badur S, Öztürk S, Ozakay A, Khalaf M, Saha D, Van Damme P. A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region. Human Vaccines &Immunotherapeutics. 2021 Oct 3;1710):3710- 28. https://doi.org/10.1080/21645515.2021.1920871
PMid:34213403 PMCid:PMC8437515
14. Foster MA, Hofmeister MG, Xing J, et al. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. Journal of Infectious Diseases. 2021;2239):1450-1459. https://doi.org/10.1093/infdis/jiab046
PMid:35238363 PMCid:PMC8892529
15. Chicago Department of Public Health. Hepatitis A Response and Immunization Program. *Chicago Health Reports*. 2021;Issue 7:45-50. Available at:https://www.chicagohan.org/documents/14171/93622/Hepatitis_A_10242017
16. Centers for Disease Control and Prevention CDC). Hepatitis A Surveillance Report. *CDC Annual Reports*. 2021. Available at: https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-a.htm
17. Hussein HK. Three years epidemiological study of acute hepatitis A infection in Al Elwyia pediatric teaching hospital, Baghdad, Iraq. Rawal Medical Journal. 2019 Oct 8;443):436-.
18. Daood II, RH I. Seroprevalence of Hepatitis A Virus HAV) in Mosul City. Medico Legal Update. 2020 Jan;201):310-4.
19. AA Darwish L, Nasrallah AA, Al Mousaw A. Hepatitis A in Kerbala: Eight Year Epidemiological Study. Kerbala Journal of Medicine. 2018 Jun 1;111):3873-83.
20. Akman AÖ, Burhan BY, Uzun AK, Taş D. Hepatitis A virus age-specific seroprevalence after the implementation of a Toddlers' Vaccination in Turkey: Shifting susceptibility to adolescents. Turk PediatriArs. 2020 Dec 16;554):370-375. https://doi.org/10.1016/j.sbspro.2011.05.114PMID: 33414654; PMCID: PMC7750331.
21. Elsabawy MN. Hepatitis gender gap in Egypt: A study in medical geography. Procedia-Social and Behavioral Sciences. 2018 Jan 1;19:121-30.https://doi.org/10.1016/j.sbspro.2011.05.114.
22. Choe YJ, Son H. The changing gender differences in hepatitis a incidence in South Korea. Vaccine. 2020 Jan 22;384):712-4. https://doi.org/10.1016/j.vaccine.2019.11.048
PMid:31787416
23. Cao G, Jing W, Liu J, Liu M. The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention. Hepatol Int. 2021 Oct;155):1068-1082.. Epub 2021 Aug 3. PMID: 34345993; PMCID: PMC8514357.https://doi.org/10.1007/s12072-021-10232-4
24. Abdullah I; Goreal A. Seroprevalence of anti-hepatitis A virus antibody in Iraq. East Mediterr Health J. 2022;2811):829–834. https://doi.org/10.26719/emhj.22.087
25. Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis. 1995 Mar;171Supplement_ 1:S15-8. https://doi.org/10.1007/s12072-021-10232-4. PMID: 7876641.
26. Arooj S, Mukhtar MU, Abbas F. An acute viral hepatitis epidemic: does ultrasound help the pediatrician? BMC Res Notes. 2021 Mar 10;141):95. https://doi.org/10.1186/s13104-021-05510-1. PMID: 33691769; PMCID: PMC7944630.
27. Han HS, Park CM, Lee DS, Sinn DH, Gil E. Evaluating mortality and recovery of extreme hyperbilirubinemia in critically ill patients by phasing the peak bilirubin level: A retrospective cohort study. PLoS One. 2021Aug5;168):e0255230. https://doi.org/10.1371/journal.pone.0255230. PMID: 34351969; PMCID: PMC8341602.
28. Jiang AA, Greenwald HS, Sheikh L, Wooten DA, Malhotra A, Schooley RT, Sweeney DA. Predictors of acute liver failure in patients with acute hepatitis A: an analysis of the 2016-2018 San Diego county hepatitis A outbreak. InOpen forum infectious-diseases 2019 Nov Vol. 6, No. 11, p. ofz467). US: Oxford University Press. https://doi.org/10.1093/ofid/ofz467 PMid:31777757 PMCid:PMC6868431
29. Anand AC, Nandi B, Acharya SK, et al. Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis. J Clin Exp Hepatol. 2020 Jul-Aug;104):339-376. Epub 2020 Apr 28. PMID: 32655238; PMCID: PMC7335721.https://doi.org/10.1016/j.jceh.2020.04.012
30. van Lennep M, Leijdekkers ML, Oors JM, Benninga MA, van Wijk MP, Singendonk MM. Clinical experience with performing esophageal function testing in children. Journal of pediatric gastroenterology and nutrition. 2021 Feb1;722):226-31. https://doi.org/10.1097/MPG.0000000000003000
PMid:33230070 PMCid:PMC7815250
31. Hrynkiewicz R, Niedźwiedzka-Rystwej P. Etiology of viral induced acute liver failure and defensins as potential therapeutic agents in ALF treatment. Front Immunol. 2023 Apr 21;14:1153528. doi: 10.3389/fimmu.2023.1153528. PMID: 37153560; PMCID:PMC10160486.https://doi.org/10.3389/fimmu.2023.1153528
PMid:37153560 PMCid:PMC10160486
32. Naher B, Islam R, Ghosal S, Nahid KL. Rukunuzzaman 2021) Seroprevalence and Co-infection of Hepatitis A and Hepatitis E Viruses in children-A hospital-based study in Bangladesh. J NeonatolClinPediatr 8: 080. of.;4:2.
33. Escobedo-Meléndez G, Fierro NA, Roman S, Maldonado-González M, Zepeda-Carrillo E, Panduro A. Prevalence of hepatitis A, B and C serological markers in children from western Mexico. ANNALS of Hepatology. 2012 Mar
34. https://doi.org/10.1016/S1665-268119)31024-5.
35. Kanda T, Sasaki R. Hepatitis A Infection in Patients with Chronic Liver Disease: Clinical Outcomes and Management. *Int J Mol Sci*. 2022;233):1267. https://doi.org/10.3390/ijms23031267
PMid:35163190 PMCid:PMC8836203
36. Thejeal RF, Abdulwahhab SB, Bahlol AR. Epidemiological study of hepatitis A infection, experience of children welfare teaching hospital: One-year analysis. EurAsian Journal of BioSciences. 2020 Aug 1;142): 6673-6677
37. Hofmeister MG, Xing J, Foster MA, et al. Hepatitis A person-to-person outbreaks: epidemiology, morbidity burden, and factors associated with hospitalization—multiple states, 2016–2019. J Infect Dis. 2021 Feb 1;2233):426-34. https://doi.org/10.1093/infdis/jiaa636
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Bandar M. Al hadeethi, AlZahraa Sh. Jasim, Batool K. Abdullah, Rabab F. Theajeal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution 4.0 International license..
